Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Lisinopril | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | Lisinopril | hsa00190 | Oxidative phosphorylation | 2.05E-04 | 4 | Q16718, Q13488, P36542, O14521 | NDUFA5, TCIRG1, ATP5C1, SDHD | More | | Lisinopril | hsa00500 | Starch and sucrose metabolism | 2.87E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Lisinopril | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Lisinopril | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Lisinopril | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | | Lisinopril | hsa03013 | RNA transport | 1.39E-04 | 12 | O14980, Q09161, O14893, Q7Z3B4, P35658, P47813, Q14152, O75822, Q14240, Q9BZI7, Q06787, P51114 | XPO1, NCBP1, GEMIN2, NUP54, NUP214, EIF1AX, EIF3A, EIF3J, EIF4A2, UPF3B, FMR1, FXR1 | More | | Lisinopril | hsa03022 | Basal transcription factors | 3.50E-02 | 3 | P20226, O00268, Q15544 | TBP, TAF4, TAF11 | More | | Lisinopril | hsa04060 | Cytokine-cytokine receptor interaction | 3.95E-02 | 11 | P27930, P08476, Q13651, P25024, P25025, Q9UBD3, P47992, P01375, P09341, P18510, Q93038 | IL1R2, INHBA, IL10RA, CXCR1, CXCR2, XCL2, XCL1, TNF, CXCL1, IL1RN, TNFRSF25 | More | | Lisinopril | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.31E-02 | 7 | P09341, P25024, P25025, P47992, Q9UBD3, Q13651, P01375 | CXCL1, CXCR1, CXCR2, XCL1, XCL2, IL10RA, TNF | More | | Lisinopril | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 6 | Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | | Lisinopril | hsa04146 | Peroxisome | 4.83E-02 | 4 | O96011, P56589, Q9UKG9, O75521 | PEX11B, PEX3, CROT, ECI2 | More | | Lisinopril | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Lisinopril | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Lisinopril | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Lisinopril | hsa04610 | Complement and coagulation cascades | 3.16E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | | Lisinopril | hsa04612 | Antigen processing and presentation | 1.81E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Lisinopril | hsa04640 | Hematopoietic cell lineage | 2.20E-02 | 8 | P13612, P27930, P15144, P25063, P09693, P01732, P13765, P01375 | ITGA4, IL1R2, ANPEP, CD24, CD3G, CD8A, HLA-DOB, TNF | More | | Lisinopril | hsa04650 | Natural killer cell mediated cytotoxicity | 4.63E-03 | 9 | P01375, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Lisinopril | hsa04657 | IL-17 signaling pathway | 3.52E-02 | 6 | O00463, Q16539, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, CXCL1, MMP9, LCN2, TNF | More | | Lisinopril | hsa04658 | Th1 and Th2 cell differentiation | 4.23E-05 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Lisinopril | hsa04659 | Th17 cell differentiation | 1.22E-03 | 11 | P25963, Q04759, Q16539, P06239, P13765, Q9UL17, P23771, P84022, Q13485, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, LCK, HLA-DOB, TBX21, GATA3, SMAD3, SMAD4, CD3G, CD247 | More | | Lisinopril | hsa04660 | T cell receptor signaling pathway | 1.60E-03 | 10 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14 | More | | Lisinopril | hsa04668 | TNF signaling pathway | 1.81E-02 | 7 | P01375, O00463, Q16539, P18848, P09341, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL1, BCL3, MMP9 | More | | Lisinopril | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Lisinopril | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Lisinopril | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Lisinopril | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Lisinopril | hsa05014 | Amyotrophic lateral sclerosis | 2.72E-02 | 10 | P01375, Q16718, O14521, P36542, P09651, Q7Z3B4, P35658, P43243, Q09161, Q16629 | TNF, NDUFA5, SDHD, ATP5C1, HNRNPA1, NUP54, NUP214, MATR3, NCBP1, SFRS7 | More | | Lisinopril | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | | Lisinopril | hsa05133 | Pertussis | 2.24E-02 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Lisinopril | hsa05140 | Leishmaniasis | 4.50E-03 | 5 | P14598, O60603, P25963, P29350, Q15080 | NCF1, TLR2, NFKBIA, PTPN6, NCF4 | More | | Lisinopril | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Lisinopril | hsa05144 | Malaria | 4.23E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Lisinopril | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | | Lisinopril | hsa05146 | Amoebiasis | 9.15E-03 | 7 | P09341, P27930, P01375, P05089, P22694, P12814, P08311 | CXCL1, IL1R2, TNF, ARG1, PRKACB, ACTN1, CTSG | More | | Lisinopril | hsa05150 | Staphylococcus aureus infection | 4.02E-03 | 6 | P21462, O75015, Q14532, P59665, P59666, P12838 | FPR1, FCGR3B, KRT32, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Lisinopril | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Lisinopril | hsa05202 | Transcriptional misregulation in cancer | 1.95E-02 | 12 | P14780, P27930, Q15744, Q16548, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, LYL1, GADD45A | More | | Lisinopril | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Lisinopril | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | | Lisinopril | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | | Lisinopril | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Lisinopril | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Lisinopril | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.52E-02 | 6 | O95267, P20963, P09693, P06239, Q04759, Q16539 | RASGRP1, CD247, CD3G, LCK, PRKCQ, MAPK14 | More | | Lisinopril | hsa05310 | Asthma | 1.29E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Lisinopril | hsa05321 | Inflammatory bowel disease | 8.46E-04 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Lisinopril | hsa05322 | Systemic lupus erythematosus | 4.08E-02 | 7 | O75015, P08246, P08311, P01375, P13765, Q16778, P12814 | FCGR3B, ELA2, CTSG, TNF, HLA-DOB, HIST2H2BE, ACTN1 | More | | Lisinopril | hsa05332 | Graft-versus-host disease | 5.27E-04 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | |